[HTML][HTML] The forefront of ovarian cancer therapy: update on PARP inhibitors

MR Mirza, RL Coleman, A González-Martín… - Annals of …, 2020 - Elsevier
Background In recurrent ovarian cancer, poly (ADP-ribose) polymerase (PARP)-inhibiting
agents have transformed the treatment of platinum-sensitive disease. New data support use …

[HTML][HTML] Metal-and metalloid-based compounds to target and reverse cancer multidrug resistance

A Valente, A Podolski-Renić, I Poetsch… - Drug Resistance …, 2021 - Elsevier
Drug resistance remains the major cause of cancer treatment failure especially at the late
stage of the disease. However, based on their versatile chemistry, metal and metalloid …

Pan-cancer landscape of homologous recombination deficiency

L Nguyen, J WM Martens, A Van Hoeck… - Nature …, 2020 - nature.com
Homologous recombination deficiency (HRD) results in impaired double strand break repair
and is a frequent driver of tumorigenesis. Here, we develop a genome-wide mutational scar …

Single duplex DNA sequencing with CODEC detects mutations with high sensitivity

JH Bae, R Liu, E Roberts, E Nguyen, S Tabrizi… - Nature Genetics, 2023 - nature.com
Detecting mutations from single DNA molecules is crucial in many fields but challenging.
Next-generation sequencing (NGS) affords tremendous throughput but cannot directly …

The genomic and transcriptional landscape of primary central nervous system lymphoma

J Radke, N Ishaque, R Koll, Z Gu, E Schumann… - Nature …, 2022 - nature.com
Primary lymphomas of the central nervous system (PCNSL) are mainly diffuse large B-cell
lymphomas (DLBCLs) confined to the central nervous system (CNS). Molecular drivers of …

Comprehensive analysis of mutational signatures reveals distinct patterns and molecular processes across 27 pediatric cancers

V Thatikonda, SMA Islam, RJ Autry, BC Jones… - Nature cancer, 2023 - nature.com
Abstract Analysis of mutational signatures can reveal underlying molecular mechanisms of
the processes that have imprinted the somatic mutations found in cancer genomes. Here, we …

Genomic features and classification of homologous recombination deficient pancreatic ductal adenocarcinoma

T Golan, GM O'Kane, RE Denroche… - Gastroenterology, 2021 - Elsevier
Background and Aims Homologous recombination deficiency (HRD) in pancreatic ductal
adenocarcinoma (PDAC), remains poorly defined beyond germline (g) alterations in …

Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer

TL Lotan, HB Kaur, DC Salles, S Murali… - Modern …, 2021 - nature.com
The homologous recombination deficiency (HRD) score integrates three DNA-based
measures of genomic instability, and has been understudied in prostate cancer. Given the …

[HTML][HTML] Spontaneous mutagenesis in human cells is controlled by REV1-Polymerase ζ and PRIMPOL

Z Gyüre, Á Póti, E Németh, B Szikriszt, R Lózsa… - Cell Reports, 2023 - cell.com
Translesion DNA synthesis (TLS) facilitates replication over damaged or difficult-to-replicate
templates by employing specialized DNA polymerases. We investigate the effect on …

Homologous recombination repair gene mutations to predict olaparib plus bevacizumab efficacy in the first-line ovarian cancer PAOLA-1/ENGOT-ov25 trial

E Pujade-Lauraine, J Brown, A Barnicle… - JCO Precision …, 2023 - ascopubs.org
PURPOSE The PAOLA-1/ENGOT-ov25 trial of maintenance olaparib plus bevacizumab for
newly diagnosed advanced high-grade ovarian cancer demonstrated a significant …